Clinical and biological distinctions between type I and type II acquired angioedema.

granulomatosis and hypercalcaemia following intravesical bacillus CalmetteGuérin immunotherapy. J Intern Med. 2002;251:272–277. 4. Buchs N, Chevrel G, Miossec P. Bacillus Calmette-Guérin induced aseptic arthritis: an experimental model of reactive arthritis. J Rheumatol. 1998;25:1662–1665. 5. Mas AJ, Romera M, Valverde Garcia J. Articular manifestations after the administration of intravesical BCG. Joint Bone Spine. 2002;69:92–98. 6. Shoenfeld Y, Aron-Maor A, Tanai A, Ehrenfeld M. BCG and autoimmunity: another two-edged sword. J Autoimmun. 2001;16:235–240. 7. Smith MD, Chandran G, Parker A, et al. Synovial membrane cytokine profiles in reactive arthritis secondary to intravesical bacillus Calmette-Guérin therapy. J Rheumatol. 1997;24:752–758. 8. Bartolomé Pacheco MJ, Martinez Taboada VM, Blanco R, Rodriguez Valverde V, Valle JI, López Hoyos M. Reactive arthritis after BCG immunotherapy: T cell analysis in peripheral blood and synovial fluid. Rheumatology. 2002;41:1119 –1125. 9. Baxter AG, Horsfall AC, Healey D, et al. Mycobacteria precipitate an SLE-like syndrome in diabetes-prone NOD mice. Immunology. 1994;83:227–231. 10. Engelman EG, Sonnenfield G, Dauphinee M. Treatment of NZB/NZW f1 hybrid mice with Mycobacterium bovis strain of BCG or type II interferon preparations accelerates autoimmune disease. Arthritis Rheum. 1981;323:1381–1387.